289
Participants
Start Date
October 18, 2018
Primary Completion Date
May 30, 2020
Study Completion Date
November 18, 2022
TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy
TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy
Placebos
placebo combine with chemotherapy
Taipei Veterans General Hospital, Taipei
Chang Gung Medical Foundation - LinKou Chang Gung Memorial Hospital, Taoyuan District
China Medical University Hospital, Taichung
National Cheng Kung University Hospital, Tainan City
TaiChung Veterans General Hospital, Taichung
Hebei Oncology Hospital, Shijiazhuang
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing
Affiliated Hospital of Guangdong Medical University, Zhanjiang
National Cancer Centre, Singapore
Fudan University Cancer Hospital, Shanghai
Shanghai General Hospital, Shanghai
Jiangsu Oncology Hospital, Nanjing
Tan Tock Seng Hospital, Singapore
Zhejiang Cancer Hospital, Hangzhou
Jiangxi Cancer Hospital, Nanchang
Fujian Medical University Union Hospital, Fuzhou
Fujian Provincial Cancer Hospital, Fuzhou
The Second Xiangya Hospital of Central South University, Changsha
Hunan Cancer Hospital, Changsha
Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & TechnologyTongji Hospital, Wuhan
Sun Yat-Sen University Cancer Center, Guangzhou
Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou
Nanfang Hospital, Guangzhou
Cancer Hospital of Shantou University Medical College, Shantou
Shenzhen People's Hospital, Shenzhen
The Fifth Affiliated Hospital Sun Yat-Sen University - Medical Oncology, Zhuhai
The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning
Liuzhou Worker's Hospital, Liuzhou
The Affiliated Cancer Hospital of Guizhou Medical University, Guiyang
Hainan General Hospital (Hainan Province People's Hospital), Haikou
West China Hospital, Sichuan University, Chengdu
Shanghai Junshi Bioscience Co., Ltd.
OTHER